LDS/Medical Tests/Low Density Lipoprotein Receptor (LDLR) Gene Mutation Analysis

Low Density Lipoprotein Receptor (LDLR) Gene Mutation Analysis

The LDLR gene codes for the synthesis of low-density lipoprotein (LDL) receptors that are present on surface membrane of most cells. The receptor can bind with the LDL and initiates the endocytosis of the LDL particles, thus helping in clearing LDL from the circulation. Mutations in LDLR gene results in defective LDL receptors leading to impairment in receptor-mediated uptake of LDL-cholesterol and the accumulation of cholesterol in the blood. Clinically LDL receptor mutations are characterized by a marked increase in serum cholesterol, deposition of cholesterol in skin, tendons and arteries (xanthoma) and premature cardiovascular disease.

LDLR gene mutation is the most common cause of familial hypercholesterolemia (FH). More than 2,000 mutations have been identified in the LDLR gene, which can be separated into 4 classes based on the phenotypic behavior. In Class I, no LDL receptor is present due to defect in its synthesis. In Class-II, LDL receptors are produced in the endoplasmic reticulum but fail to get transported to the Golgi for further processing. In Class-III, LDL receptors are expressed in cell surface but are defective in binding LDL. In Class-IV, the LDL receptor can bind to the LDL but fails to get internalized by the cell. The majority of LDLR gene mutations involve are small point mutations (missense or nonsense) or small insertions or deletions and are detectable by sequencing. Approximately 10% of LDLR mutations are large intragenic rearrangements (large exon deletions and duplications).

Most people with familial hypercholesterolemia are heterozygous with one mutated copy of the LDLR gene leading to 50% reduction in LDL clearance. It is one of the most common genetic metabolic disorders with an incidence rate of 1 in 500 persons (US). The incidence rate is even higher in some founder populations such as those of French Canadian, Ashkenazi Jewish, Lebanese, and South African descent. Both the serum cholesterol (>270 mg/dl) and LDL-C (>190 mg/dL) levels are elevated, and most individuals develop cardiovascular disease in early middle age. Rarely, a person inherits two mutated copies of the LDLR gene (homozygous or compound heterozygous familial hypercholesterolemia). It is more severe form of the disease with an incidence of 1 in 250,000-400,000. The serum cholesterol level is severely elevated (generally >650 mg/dL) and is usually characterized by the development of atherosclerosis in early childhood. Other rare cause of familial hypercholesterolemia includes mutation in ABCG5, ABCG8, APOB, LDLR, LDLRAP1, and PCSK9 genes. Identification of these genetic mutations are helpful for the effective therapeutic plan.

  • Used in the confirmatory diagnosis of familial hypercholesterolemia
  • Screening of at-risk family members for early diagnosis
  • Assessment of carrier status in family with a member diagnosed with familial hypercholesterolemia
Mutation in LDLR gene confirms the diagnosis of familial hypercholesterolemia.

Negative for mutations or pathogenic variants in LDLR gene

Next Generation Sequencing with Microarray Confirmation, allele specific primer extension (ARMS).

Whole blood (EDTA or ACD).

Stability

  • Ambient: 2-3 days
  • Refrigerated: 7 days
  • Frozen: unacceptable
Mutational analysis of ABCG5, ABCG8, APOB, LDLR, LDLRAP1, and PCSK9 genes, Serum cholesterol, LDL-cholesterol, Lipid Panel, lipoprotein electrophoresis, functional assay of LDL receptor, Lp(a).
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login